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ghrelin and nesfatin-1
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New findings
 What is the central question of this study?
Does mammalian target of rapamycin (mTOR) signalling in the dorsal vagal complex
contribute to the modulation of energy homeostasis?
 What is the main finding and its importance?
Our study shows, for the first time, that mTOR signalling in neurons of the dorsal motor
nucleus of the vagus regulates both the nutrient and the hormonal signals for the modulation
of food intake. These results imply that mTOR signalling in the hindbrain may serve as a
potential target for treatment of obesity and appetite-related disorders.
Previous studies have demonstrated that mammalian target of rapamycin (mTOR) signalling in
the hypothalamus is involved in the control of energy homeostasis. The aim of this study was to
characterize the effect of mTOR signalling in the dorsal motor nucleus of the vagus (DMNV) on
energy intake. Phospho-mTORwas detected in theDMNVneurons, and its levels were increased
byenergydeprivation.Rapamycinsignificantly inhibitedmTORactivityandreduced food intake
when administrated into the fourth ventricle. Exposure of DMNV neurons to ghrelin increased
the phosphorylation of mTOR. Injection of ghrelin into the fourth ventricle significantly
increased food intake relative to the control vehicle. Pretreatment with rapamycin for 15min
attenuated the orexigenic effect of ghrelin. A reduction in the phosphorylation of mTOR was
observed following injection of nesfatin-1 into the fourth ventricle. When administrated by
injection into the fourth ventricle, nesfatin-1 suppressed food intake in comparison with the
controlvehicle.Theanorexigeniceffectofnesfatin-1wassignificantlyattenuatedbypretreatment
with leucine for 15min. All these findings suggest that mTOR signalling in the DMNV neurons
regulates both the nutrient and the hormonal signals for the modulation of food intake.
(Resubmitted 1 July 2013; accepted after revision 16 August 2013; first published online 16 August 2013)
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Introduction
The mammalian target of rapamycin (mTOR), a highly
conserved serine–threonine kinase, has been reported to
serve as an intracellular ATP sensor (Dennis et al. 2001;
Inoki et al. 2005). In vitro studies have demonstrated that
cellular levels of ATP regulate mTOR signalling (Dennis
et al. 2001; Inoki et al. 2005). Aberrant mTOR activity is
linked to diabetes and obesity, and a significant elevation
of mTOR signalling has been observed in the liver and
skeletal muscle of insulin-resistant, obese rats maintained
on a high-fat diet (Khamzina et al. 2005). In contrast,
absence of the mTOR downstream target, S6 kinase 1,
protects against diet-induced obesity and improves insulin
sensitivity in mice (Um et al. 2004). Gastric mTOR has
been demonstrated to be critical for the production of two
DOI: 10.1113/expphysiol.2013.074930 C© 2013 The Authors. Experimental Physiology C© 2013 The Physiological Society
Exp Physiol 98.12 (2013) pp 1696–1704 mTOR in the dorsal motor nucleus of the vagus 1697
important gastric hormones derived from the X/A-like
endocrine cells, ghrelin (Xu et al. 2009, 2010) andnesfatin-
1 (Li et al. 2012), which modulate food intake (Tschop
et al. 2000; Nakazato et al. 2001; Oh-I et al. 2006; Stengel
et al. 2009; Xu et al. 2010; Stengel & Tache´, 2012) and
glucose homeostasis (Sun et al. 2006; Yang et al. 2010; Xu
et al. 2012).
Signalling by mTOR in hypothalamic neurons is
involved in neuronal sensing of nutrient availability, and
regulates food intake and energy balance, suggesting that
mTOR signalling in theCNS is crucial for the regulation of
energymetabolism (Cota et al. 2006;Mori et al. 2009). It is
currently unknownwhethermTOR signalling is present in
the dorsal vagal complex (DVC), a group of nuclei critical
for the co-ordination of gastrointestinal functions (Zheng
et al. 2005; Travagli et al. 2006; Browning&Travagli, 2011).
The DVC, a paired structure located in the dorsal, caudal
medulla alongside the central canal, which is contiguous
with the fourth ventricle, is composed of three adjacent
and functionally integrated nuclei, namely the nucleus
tractus solitarii (NTS), the area postrema and the dorsal
motor nucleus of the vagus (DMNV). The DVC is a
critical relay in vagovagal circuits. Afferent vagal fibres
from the gastrointestinal tract synapse on interneurons
locatedwithin theNTS. These neurons synapse on efferent
vagal motor neurons in the DMNV. Preganglionic efferent
vagal fibres project to ganglia in the upper gastrointestinal
tract, providing parasympathetic control of many aspects
of gastrointestinal function, including motility, secretion
and absorption (Zheng et al. 2005; Travagli et al. 2006;
Browning & Travagli, 2011).
While fuel-sensing molecules, such as AMP-activated
kinase (AMPK; Minokoshi et al. 2004; Yang et al.
2010; Lam et al. 2011) and mTOR (Cota et al. 2006;
Mori et al. 2009), have been implicated in the co-
ordination of energy supplies, food intake and energy
expenditure in the hypothalamic neurons, their roles in
the dorsal vagal complex are less well studied. Previous
reports have demonstrated that AMPK activity in the
hindbrain contributes to control of energy balance
through regulation of food intake and energy expenditure
(Hayes et al. 2009). The present study examines mTOR
signalling in the dorsal vagal complex. We report that
alterations in mTOR signalling in the DMNV in response
to fasting and the gastric hormones ghrelin and nesfatin-1
are involved in the regulation of food intake.
Methods
Ethical approval
The animals used in this studywere handled in accordance
with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(NIH publication no. 85-23, revised 1996), and all the
experimental protocols (08402) were approved by the
University of Michigan Committee on the Use and Care
of Animals.
Chemicals and solutions
Neurobasal medium, phosphate buffer solution (PBS),
B27 supplement, L-glutamine, penicillin and streptomycin
were purchased from Gibco (Grand Island, NY, USA).
β-Fibroblast growth factor (βFGF) was from Invitrogen
(Carlsbad, CA, USA). Poly-L-lysine and Triton X-100
were purchased from Sigma-Aldrich (St Louis, MO,
USA). Ghrelin and nesfatin-1 peptides were from
Phoenix Pharmaceuticals (Burlingame, CA, USA).
Rabbit anti-phospho-mTOR (Ser2448) polyclonal
antibody, phospho-mTOR (Ser2448) and mTOR mouse
monoclonal antibodies, phosphorylated ribosomal
protein S6 (pS6; ser235/236) mouse antibody and S6
ribosomal mouse antibody were from Cell Signaling
Technology (Beverly, MA, USA). The secondary
antibodies fluorescein isothiocyanate-conjugated
goat anti-mouse IgG and tetramethylrhodamine
isothiocyanate-conjugated goat anti-rabbit IgG were
obtained from Jackson ImmunoResearch (West Grove,
PA, USA). Intracerebroventricular cannulae were
purchased from Plastics One (Roanoke, VA, USA) and
cut to 7.4 mm.
Animal care
Animals were housed in a temperature-controlled
environment with a 12 h–12 h light–dark cycle and access
to food and water ad libitum except when indicated.
Cannulation of the fourth ventricle
Male Sprague–Dawley rats weighing 200–250 g were
anaesthetized by I.P. injection of a mixture of xylazine and
ketamine (13 and 87mg (kg bodyweight)−1, respectively).
A 26 gauge single-lumen cannula was introduced into the
fourth ventricle stereotactically according to co-ordinates
publishedbyPaxinos andWatson (1998):mid-line, 13mm
caudal to bregma and 7.4 mm deep, with the incisor
bar set 3.3 mm below the interaural line. Screws were
placed into the skull surrounding the cannula, and the
cannula was secured with craniofacial cement. Finally, a
sterile internal cannulawasplaced tomaintainpatency and
prevent infection. On postprocedure day 3, the position of
the cannula was tested by intracerebroventricular (I.C.V.)
injection of 5-thio-D-glucose (210μg in 3μl PBS). A
>50% rise in blood glucose in response to 5-thio-D-
glucose was considered to be confirmation of the correct
position of the cannula. On postprocedure day 7, animals
were acclimated and mock-injected with 2μl of artificial
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cerebrospinal fluid. On postprocedure day 9, animals
underwent 2μl I.C.V. injection of rapamycin, leucine,
ghrelin, nesfatin-1 or artificial cerebrospinal fluid over
1 min either at 18.00 h in the dark phase or at 08.00 h
in the light phase. The doses of ghrelin and nesfatin-1
were chosen based on published literature (Nakazato et al.
2001; Oh-I et al. 2006) and previous experiments in our
laboratory (Zhang et al. 2001). Rats were group housed,
and food intake in ad libitum-fed animals was measured
before and after I.C.V. injection.
Neuronal culture of the dorsal motor nucleus
Dorsalmotornucleusneuronswere isolated fromneonatal
Sprague–Dawley rats (Charles River, Wilmington, MA,
USA) as described previously (Zhang et al. 2004, 2006).
The procedures used for the care and killing of the animals
were approved by the University of Michigan Committee
on Use and Care of Animals. Briefly, rats were killed
by CO2 inhalation followed by bilateral pneumothorax.
The brainstem was rapidly removed and chilled at 0◦C in
a dissection solution containing (mM): 138 NaCl, 4 KCl,
1MgCl2, 2 CaCl2, 20 glucose and 10 Hepes. Tissue blocks
were prepared and sectioned transversely into 400-μm-
thick slices at the level of the obex using a Vibratome
3000 (Redding, CA, USA). TheDMNV area was identified
under a dissecting microscope as the area immediately
ventral to the NTS and dorsal to the XII nucleus. The
DMNV tissue was excised and then digested in an enzyme
solution containing protease type XIV (0.6 mgml−1) and
trypsin type I (0.4 mgml−1) at 32◦C for 30min. The tissue
was then dissociated by gentle trituration with pipettes.
Cells were plated onto poly-L-lysine-coated culture dishes
and chamber slides. Neurons were maintained at 37◦C
in an atmosphere of air supplemented with 5% CO2
in serum-free culture media consisting of Neurobasal
mediumcontaining 2%B27 supplement, 2 mMglutamine,
1% penicillin and streptomycin, and 5 ngml−1 βFGF.
After 4 days, one-half of the medium was replaced, and
experiments were conducted at 7 days.
Immunofluorescence
Adult Animals were deeply anaesthetized by an I.M.
injection of sodium pentobarbital at a dose of 75mg (kg
body weight)−1 and killed by bilateral pneumothorax.
Intracardiac perfusion with 4% paraformaldehyde,
preparation of tissue blocks and sectioning at a thickness
of 10μmwere performed as described previously (Zhang
et al. 2004). Slides at the level of the area postrema
were first washed in PBS for 30min, then incubated
with a blocking solution (10% normal goat serum, 3%
bovine serum albumin and 0.2% Triton X-100 in PBS,
pH 7.4) for 1 h at room temperature. Sections were then
treated with primary antibody or control IgG at 4◦C
for 24 h, washed in PBS, and treated with secondary
antibody for 1 h at room temperature. Finally, slides were
incubated with DAPI (1:5000 dilution) and mounted
with ProLong Gold antifade reagent. All antibodies were
diluted in blocking solution. The primary antibodies
used included mouse anti-Hu (1:100 dilution) and rabbit
anti-pmTOR (1:100 dilution). The control antibodies
used were mouse or rabbit IgG. Tetramethylrhodamine
isothiocyanate-conjugated goat anti-rabbit IgG (1:100
dilution) and fluorescein isothiocyanate-conjugated goat
anti-mouse IgG (1:100 dilution) were used as secondary
antibodies. Slides were viewed using a fluorescence
microscope (Nikon Eclipse Ti-U; Nikon Inc., Melville,
NY, USA). The DMNV was identified as described in the
previous subsection. The positive signal was identified and
calculated using the following criteria. Relative optical
densities were established for the regions of interest by
Image-Pro Plus (Media Cybernetics Inc., Silver Spring,
MD, USA). The results were expressed as the difference
in grey-scale levels, comparing regions of interest and
the background regions in the same section. A change
of ≥100% in optical density was used as the threshold
for positive cells. Four sections from the same animal
were counted and averaged. Neurons stained positively
for phospho-mTOR were counted and expressed as the
percentage of Hu-positive cells. Results are given as
means± SEM.
Western blotting
After treatment, DMNV neuronal cultures were
homogenized in 60μl ice-cold lysis buffer containing
20mM Tris–HCl (pH 7.5), 150mM NaCl, 1 mM
Na2EDTA, 1mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mMβ-glycerophosphate, 1 mMNa3VO4,
1μgml−1 leupeptin and 1mM phenylmethylsulfonyl
fluoride, then centrifuged at 12,000g at 4◦C for 20min.
Equal amounts of protein (∼30–40μg) from each
sample were subjected to electrophoretic separation
on a 10% polyacrylamide gel (BioRad, Hercules, CA,
USA), then transferred onto an ImmobilonTM PVDF
membrane (BioRad). Membrane blots were blocked at
room temperature for 1 h in 5% milk in Tris-buffered
saline (TBS)–Tween 20 (0.05%), then incubated overnight
in primary antibodies against mTOR or phospho-
mTOR (1:1000 dilution) from Cell Signaling Technology
(Danvers, MA, USA). Membranes were washed three
times in TBS–Tween (0.05%), then incubated for 1 h
with secondary antibody diluted 1:4000 in 5% TBS–
Tween (0.05%). Detection was performed using Lumi-
Light Blotting Substrate (Roche, Indianapolis, IN,USA)or
SuperSignal West Femto Maximum Sensitivity Substrate
(Thermo Scientific, Rockford, IL, USA).
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Data analysis
Results are expressed asmeans± SEM.Datawere analysed
usingANOVAandStudent’s unpaired t test as appropriate.
Significance was accepted as P < 0.05.
Results
mTOR signalling in the DVC
As shown in Fig. 1A, phospho-mTOR was detected in
the majority of DMNV neurons and a few NTS neurons,
Figure 1. Mammalian target of rapamycin (mTOR) signalling in
neurons of the dorsal motor nucleus of the vagus (DMNV)
A, localization of phospho-mTOR (Ser2448) in the rat dorsal
vagal complex. Left panel, control antibody showed no
staining; and right panel, specific staining (green) of
phospho-mTOR (pmTOR) in DMNV neurons. Nuclei were
stained with DAPI (blue). Scale bar represents 20 μm. B, effects
of fasting on phosphorylation of mTOR in DMNV neurons.
Phospho-mTOR and Hu (a neuronal marker) were stained with
tetramethylrhodamine isothiocyanate (red) and fluorescein
isothiocyanate (green), respectively. Shown are merged
stainings (yellow) from fed rats or rats fasted for 24 h. Neurons
stained positive for phospho-mTOR were counted and
calculated as the percentage of Hu-positive cells. Results are
shown as means + SEM. ∗P < 0.05 relative to fed animals; n = 7.
suggesting the presence of mTOR signalling in the DVC.
Nopositive signalwas observed in the control IgG staining.
Given that mTOR signalling was detected mainly in the
DMNV neurons, we focused our study on this nucleus
instead of on the NTS. We first examined alterations
in phosphor-mTOR in DMNV neurons in response to
fasting. As shown in Fig. 1B, fasting for 24 h significantly
increased thephosphorylationofmTOR inHu(aneuronal
marker)-positive DMNV neurons relative to the fed
animals (81± 6% in fasted mice versus 14± 9% in fed
animals, P < 0.01), suggesting an increase in the mTOR
signalling.
Regulation of food intake by mTOR signalling in
DMNV neurons
IfmTORsignalling contributes to energyhomeostasis, one
would expect that inhibition of mTOR signalling in the
Figure 2. Regulation of food intake by mTOR signalling
A, inhibition of mTOR signalling by rapamycin. Cultured DMNV
neurons were treated with rapamycin at doses of 5 and 50 nM
for 30 min. A representative Western blot is shown. The signal
intensity of phospho-mTOR was measured, normalized to total
mTOR and shown as the mean + SEM. ∗P < 0.05 relative to
control; n = 3. B, effects of rapamycin on food intake.
Rapamycin was administrated by fourth intracerebroventricular
(I.C.V.) injection. Results are shown as means ± SEM. ∗P < 0.05
relative to control; n = 8.
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hindbrain would alter food intake. Rapamycin, a specific
inhibitor of mTOR signalling, was used in the following
experiments to verify this concept. We first examined
the effect of rapamycin on mTOR signalling in primary
DMNV cultures. Cells were incubated with different
concentrations of rapamycin for 30min. As shown in Fig.
2A, rapamycin at the doses of 5 and 50 nM significantly
decreased levels of phospho-mTOR, suggesting inhibition
of mTOR signalling in cultured DMNV neurons.
To examine the effect ofmTORsignalling in theDVCon
food intake, rats were treated with fourth I.C.V. injection
of either rapamycin at a dose of 50μg in 2μl CSF or
vehicle. As shown in Fig. 2B, relative to the control
rats receiving vehicle administration, animals treated
with fourth I.C.V. injection of rapamycin demonstrated a
significant decrease in food intake, with persistent effects
lasting for up to 3 days.
Effects of ghrelin on mTOR signalling and food intake
Gastric hormones, such as ghrelin and nesfatin-1, have
been reported to regulate food intake by a central
mechanism.We next examined whether mTOR signalling
in the DMNV is involved in ghrelin-induced stimulation
of food intake. As shown in Fig. 3A, treatment of cultured
DMNV neurons with 20 and 200 nM of ghrelin for
30min significantly increased the levels of phosphor-
mTOR. The doses of ghrelin were chosen based on the
literature and previous experiments in our laboratory.
Fourth I.C.V. injection of ghrelin significantly increased
the phosphorylation of mTOR in the DMNV neurons
stained positively for Hu, a neuronal marker (Fig.
3B; 61± 14 versus 22± 10% of control, P < 0.05).
Administration of 5 and 10μg ghrelin into the fourth
ventricle significantly increased the food intake during
the light phase (Fig. 3C). Pretreatment with rapamycin
Figure 3. Effects of ghrelin on mTOR signalling and food intake
A, effects of ghrelin on mTOR signalling in cultured DMNV neurons. The signal intensity of phosphor-
mTOR was measured, normalized to total mTOR and shown as the mean + SEM. ∗P < 0.05 relative to
control; n = 3. B, effects of ghrelin on mTOR signalling in rats. Ghrelin or artificial cerebrospinal fluid
was administrated by fourth I.C.V. injection. Phospho-mTOR (red) and Hu (green) were detected by
immunofluorsecent staining. The results shown are representative of six animals. C, effects of ghrelin
on food intake. Ghrelin administrated by fourth I.C.V. injection induced a significant increase in food
intake relative to control animals during the light phase. Results are shown as means + SEM. ∗P < 0.05
relative to control; n = 6. There is a significant difference between the food intake in animals treated
with ghrelin at the doses of 5 and 10 μg at 3 and 4 h time points. D, mTOR-dependent modulation of
food intake by ghrelin. Pretreatment with rapamycin for 15 min markedly attenuated the orexigenic
effect of ghrelin. Results are shown as means + SEM. ∗P < 0.05 relative to control; n = 6.
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(37.5μg) for 15min attenuated the orexigenic effect of
10μg ghrelin (Fig. 3D). These results suggest that ghrelin
stimulates food intake by activation of mTOR signalling
in DMNV neurons.
Effects of nesfatin-1 on mTOR signalling
and food intake
Next, the effect of nesfatin-1, a gastric anorexigenic
hormone, onmTOR signalling in theDMNVneurons and
food intakewas investigated. As shown in Fig. 4A, cultured
DMNV neurons exposed to 0.1 and 1 nM of nesfatin-1
for 30min demonstrated a significant decrease in levels
of phospho-mTOR, suggesting an inhibition of mTOR
signalling. A similar reduction in levels of phosphor-
mTOR was observed in DMNV neurons when exposed to
nesfatin-1 by fourth I.C.V. injection (Fig. 4B; (4± 5 versus
22± 10% of control, P < 0.05). Nesfatin-1 (0.2 and 2μg)
administrated by fourth I.C.V. injection markedly reduced
food intake during the dark phase (Fig. 4C). Pretreatment
with leucine (1μg for 15min), a branched-chain α-
amino acid with potent agonism of mTOR signalling,
significantly attenuated the anorexigenic effect of 2μg
nesfatin-1 (Fig. 4D).
Combined effects of ghrelin and nesfatin-1 on mTOR
signalling and food intake
The combined effects of ghrelin and nesfatin-1
were examined. As shown in Fig. 5A, simultaneous
administration of ghrelin (5μg) and nesfatin-1 (2μg)
significantly attenuated the activation of mTOR signalling
in DMNV neurons relative to ghrelin alone (Fig. 5A),
accompanied by amarked reduction in food intake relative
to ghrelin treatment alone (Fig. 5B).
Figure 4. Effects of nesfatin-1 on mTOR signalling and food intake
A, effects of nesfatin-1 on mTOR signalling in cultured DMNV neurons. The signal intensity of phosphor-
mTOR was measured, normalized to total mTOR and shown as the mean + SEM. ∗P < 0.05 relative to
control; n = 3. B, effects of nesfatin-1 on mTOR signalling in rats. Nesfatin-1 was administrated by fourth
I.C.V. injection. Phospho-mTOR (red) and Hu (green) were detected by immunofluorsecent staining.
The results shown are representative of six animals. C, effect of nesfatin-1 on food intake. Nesfatin-1
administrated by fourth I.C.V. injection significantly reduced food intake relative to control animals.
Results are shown as means + SEM. ∗P < 0.05 relative to control; n = 6. D, mTOR-dependent modulation
of food intake by nesfatin-1. Pretreatmentwith leucine for 15 minmarkedly attenuated the anorexigenic
effect of nesfatin-1. Results are shown as means + SEM. ∗P < 0.05 relative to control; n = 6.
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Discussion
The present study demonstrates that mTOR signalling
in DMNV neurons is involved in the regulation of
food intake. This general conclusion is supported
by the following five distinct observations: (i) mTOR
signalling is present in DMNV neurons, and its
activity is upregulated by fasting; (ii) inhibition of
mTOR signalling by rapamycin decreases food intake;
(iii) ghrelin administrated by fourth I.C.V. injection
markedly increases food intake, and this effect is mediated
by activation of mTOR signalling in DMNV neurons;
(iv) in contrast, nesfatin-1 decreases food intake through
inhibition of mTOR signalling in DMNV neurons; and
(v) simultaneous administration of ghrelin and nesfatin-
1 blunts increases in mTOR signalling and food intake
induced by ghrelin.
Signalling by mTOR in the hypothalamus is known
to be involved in the regulation of food intake and
energy expenditure (Cota et al. 2006; Mori et al. 2009).
Figure 5. Combined effects of ghrelin and nesfatin-1 on mTOR
signalling and food intake
A, effects on mTOR signalling in vivo. A combination of ghrelin
(5 μg) and nesfatin-1 (2 μg), ghrelin (5 μg) alone or vehicle was
administrated by fourth I.C.V. injection. Phospho-mTOR and Hu
were detected by immunofluorsecent staining. Neurons stained
positively for phospho-mTOR were counted and expressed as a
percentage of Hu-positive cells. Results are shown as
means + SEM. ∗P < 0.05; n = 5. B, effects on food intake.
Results are shown as means + SEM. ∗P < 0.05 relative to control;
†P < 0.05 relative to ghrelin alone; n = 5.
Whether extrahypothalamic mTOR signalling in the CNS
contributes to the control of energy homeostasis has
not been previously demonstrated. Here, we demonstrate
that mTOR signalling in DMNV neurons is responsive
to energy status and to both ghrelin and nesfatin-
1, two important feeding peptide hormones secreted
by gastric endocrine cells, and that pharmacological
inhibition of mTOR signalling in these nuclei drives a
reduction in food intake. Furthermore, mTOR signalling
is an important fuel-sensing mechanism, which regulates
extracellular signals provided by gastric hormones.
Together with a previous report by Mori et al. (2009),
in which mTOR activation in proopiomelanocortin
(POMC)neuronswas demonstrated to block the catabolic
function of these neurons, to promote nutrient intake and
increase adiposity, these observations suggest a positive
relationship between neuronal mTOR activity and food
intake in the CNS. In contrast, in an earlier study by
Cota et al. (2006), using pharmacological approaches to
inhibit mTOR signalling in hypothalamus, mTOR activity
was shown to be related negatively to energy intake. In
addition, activation of mTOR signalling by leucine in
the NTS has been reported to decrease the meal size
(Blouet & Schwartz, 2012). The discrepancy between
these experimental results may implicate the presence of
differential mechanisms involved in the control of energy
homeostasis. The present study supports the concept that
the DVC is critical for the control of energy homeostasis
based on previous observations that a reduction of
energy availability in DVC neurons triggers behavioural,
endocrine and autonomic responses that act to restore
energy balance, and that NTS neurons express AMPK
and contribute to the control of food intake (Hayes
et al. 2009). Taken together, these studies indicate that
mTOR signalling is present and contributes to the control
of energy homeostasis across the neuraxis rather than
through a localized effect on a single brain region.
Food intake is controlled by the hypothalamus, which
integrates a variety of orexigenic and anorexigenic signals
from both central and peripheral sources. Ghrelin and
nesfatin-1, two important gastric hormones secreted
by the X/A-like endocrine cells, represent hunger and
satiety signals that have been demonstrated to act on
hypothalamic neurons (Tschop et al. 2000; Nakazato et
al. 2001; Oh-I et al. 2006; Stengel et al. 2009; Stengel
& Tache´, 2012). The present study extends the sites of
action for these hormones to the dorsal vagal neurons.
Employing a pharmacological approach to alter levels of
mTOR activity, we found that both the orexigenic signal,
ghrelin, and the anorexigenic signal, nesfatin-1, converge
on mTOR signalling in the DMNV neurons to regulate
food intake differentially. Unlike the short-term effects
of ghrelin and nesfatin-1, I.C.V. injection of rapamycin
causes long-lasting effects on food intake. Signalling by
mTOR may therefore serve as a potential target for
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therapeutical strategies targeted at obesity and appetite-
related disorders. The upstream signalling molecules
linking ghrelin and nesfatin-1 with mTOR in the DMNV
neurons are currently unknown. Previous studies have
reported that AMPK is an important negative regulator
formTOR signalling and that ghrelinmay activate AMPK;
however, we did not detect an obvious signal for pAMPK,
an active form of AMPK, in the DMNV neurons (Zhang
W, Zhang C, MW Mulholland, unpublished data). The
role of AMPK in mediation of the effect of ghrelin on
mTOR signalling in DMNV neurons is unclear.
Limitations exist for both genetic and pharmacological
approaches that seek to assess the physiological role
of mTOR signalling in the control of energy balance.
For genetic approaches, chronic changes in the levels of
mTOR activity may result in altered neuronal circuitry,
thereby producing distinct alterations, as observed in the
study by Mori et al. (2009). Pharmacological approaches
are limited by the specifity and the solubility of drugs.
However, unlike genetic approaches, alterations induced
by pharmacological agents are acute and reversible. It has
been reported that mTOR signalling in the hypothalamus
can be effectively and reversibly inhibited or activated by
third I.C.V. injection of rapamycin or leucine, respectively
(Cota et al. 2006). As expected, rapamycin and leucine
were demonstrated to be effective for the inhibition
and stimulation of mTOR signalling, respectively, when
delivered by fourth I.C.V. injection.
In conclusion, this study provides the first evidence that
mTOR signalling in the DMNV neurons may integrate
both the nutrient and the hormonal signals for the
maintenance of energy homeostasis. These results imply
that mTOR signalling in the hindbrain may serve as a
potential target for treatment of obesity and appetite-
related disorders.
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